BIO

Natalie Nairn is the Cofounder, CEO, and CSO of Cyclera Therapeutics, a company creating revolutionary extracellular protein degraders to do what other drugs cannot. She has more than 20 years of experience in the biotechnology industry developing protein therapeutics from discovery through late-stage clinical development. Prior to Cyclera, Dr. Nairn was Vice President, CDP Therapeutics at Blaze Bioscience. Many programs were developed in this role, including the CYpHER technology that Dr. Nairn licensed into Cyclera. She was one of the initial 5 employees at Allozyne, a company developing next-generation ADCs, PEGylated proteins, and bispecifics. Dr. Nairn had growing responsibilities overseeing design, chemistry, formulation, and protein biochemistry. Her therapeutic career began at Corixa, developing cancer vaccine approaches.

Dr. Nairn earned her Ph.D. in Chemical Engineering from California Institute of Technology, where she was an NSF Graduate Research Fellow. Prior, she earned an M.S. from Caltech and a B.S.ChE from University of Washington in chemical engineering. Dr. Nairn is an inventor on 13 US patents.